JP2022544538A5 - - Google Patents

Info

Publication number
JP2022544538A5
JP2022544538A5 JP2022509053A JP2022509053A JP2022544538A5 JP 2022544538 A5 JP2022544538 A5 JP 2022544538A5 JP 2022509053 A JP2022509053 A JP 2022509053A JP 2022509053 A JP2022509053 A JP 2022509053A JP 2022544538 A5 JP2022544538 A5 JP 2022544538A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
alkoxy
independently selected
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022509053A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544538A (ja
JP7689110B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/046546 external-priority patent/WO2021030766A1/en
Publication of JP2022544538A publication Critical patent/JP2022544538A/ja
Publication of JP2022544538A5 publication Critical patent/JP2022544538A5/ja
Priority to JP2025087494A priority Critical patent/JP2025122671A/ja
Application granted granted Critical
Publication of JP7689110B2 publication Critical patent/JP7689110B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022509053A 2019-08-15 2020-08-14 脊髄性筋萎縮症のための併用療法 Active JP7689110B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025087494A JP2025122671A (ja) 2019-08-15 2025-05-26 脊髄性筋萎縮症のための併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962887579P 2019-08-15 2019-08-15
US62/887,579 2019-08-15
PCT/US2020/046546 WO2021030766A1 (en) 2019-08-15 2020-08-14 Combination therapy for spinal muscular atrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025087494A Division JP2025122671A (ja) 2019-08-15 2025-05-26 脊髄性筋萎縮症のための併用療法

Publications (3)

Publication Number Publication Date
JP2022544538A JP2022544538A (ja) 2022-10-19
JP2022544538A5 true JP2022544538A5 (enExample) 2023-08-22
JP7689110B2 JP7689110B2 (ja) 2025-06-05

Family

ID=74570741

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022509053A Active JP7689110B2 (ja) 2019-08-15 2020-08-14 脊髄性筋萎縮症のための併用療法
JP2025087494A Pending JP2025122671A (ja) 2019-08-15 2025-05-26 脊髄性筋萎縮症のための併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025087494A Pending JP2025122671A (ja) 2019-08-15 2025-05-26 脊髄性筋萎縮症のための併用療法

Country Status (4)

Country Link
US (1) US20220280548A1 (enExample)
EP (1) EP4013387A4 (enExample)
JP (2) JP7689110B2 (enExample)
WO (1) WO2021030766A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4426306A1 (en) * 2021-10-06 2024-09-11 F. Hoffmann-La Roche AG Novel combined administration
WO2023183304A2 (en) * 2022-03-21 2023-09-28 Capsigen Inc. Transcription-dependent directed evolution of aav capsids having enhanced tropism
CN118005654A (zh) * 2022-04-18 2024-05-10 深圳市塔吉瑞生物医药有限公司 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途
JP2025534681A (ja) * 2022-10-14 2025-10-17 ジェネンテック， インコーポレイテッド 脊髄性筋萎縮症の治療方法
IL326390A (en) 2023-08-10 2026-04-01 Univ Pennsylvania Compositions and methods for treatment of spinal muscular atrophy
CN118045206B (zh) * 2024-04-12 2024-07-05 四川至善唯新生物科技有限公司 一种治疗脊髓型肌肉萎缩的药物组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220084437A (ko) 2009-06-17 2022-06-21 바이오젠 엠에이 인코포레이티드 대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법
US20140343127A1 (en) * 2011-11-11 2014-11-20 Santaris Pharma A/S a corporation Compounds for the modulation of smn2 splicing
JP2015523854A (ja) * 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Ｓｍｎ遺伝子ファミリー発現を調節するための組成物及び方法
BR112015027336A2 (pt) 2013-05-01 2017-09-26 Genzyme Corp composições e processos para tratamento de atrofia muscular espinhal
AU2016353961B2 (en) 2015-11-12 2019-08-29 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
AU2016370630B2 (en) * 2015-12-14 2023-04-13 The Trustees Of The University Of Pennsylvania Adeno-associated viral vectors useful in treatment of spinal muscular atropy
PL3484524T3 (pl) * 2016-07-15 2023-03-20 Ionis Pharmaceuticals, Inc. Związki i sposoby modulacji smn2
JP2021534154A (ja) * 2018-08-15 2021-12-09 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 脊髄性筋萎縮症のための併用療法

Similar Documents

Publication Publication Date Title
AU2023203112B2 (en) Peptide oligonucleotide conjugates
ES3029140T3 (en) Substituted aminothiazoles as dgkzeta inhibitors for immune activation
US20250262235A1 (en) Oligonucleotide compositions and methods relating thereto
US20250302995A1 (en) Oligonucleotide compositions and methods thereof
JP2024539228A (ja) 含窒素四環式化合物、その調製方法及びその医薬的使用
JP2021048886A (ja) 修飾されたサブユニット間結合および／または末端基を有するオリゴヌクレオチドアナログ
US20240026358A1 (en) Oligonucleotide compositions and methods thereof
US8236835B2 (en) Heterocyclic inhibitors of stearoyl-CoA desaturase
JP2021534124A5 (enExample)
KR101584826B1 (ko) 스테아로일-ＣｏＡ 데새투라제의 헤테로시클릭 억제제
JP2019510787A5 (enExample)
JP2019518071A (ja) Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物
JP2016502519A (ja) Ｈｂｖ集合エフェクターの代替的使用
JP2020513034A (ja) プロテインキナーゼ阻害剤としての１ｈ−イミダゾ［４，５−ｈ］キナゾリン系化合物
ES2437346T3 (es) Procedimiento para la producción de derivado de diamina
JP2025505644A5 (enExample)
JP2025505200A5 (enExample)
TW201117812A (en) Macrocyclic serine protease inhibitors
TW200927127A (en) Agent for overcoming resistance to anti-cancer agent
CN105315319B (zh) 丙型肝炎病毒抑制剂及其应用
CA2664376C (en) Polycyclic agents for the treatment of respiratory syncytial virus infections
WO2022229351A1 (en) Selective inhibitors of rock2 for the treatment of muscular dystrophy
JP2020509997A5 (enExample)
JP2021536472A5 (enExample)
JP2022519764A (ja) 二環式スルホンアミド